Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients.
Kovarik
J M
JM
Novartis Pharmaceuticals, Basel, Switzerland.
Korn
A
A
Chodoff
L
L
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000097:blood / Q000276:immunology; D000077552:Basiliximab; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D011241:Prednisone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000097:blood / Q000276:immunology; D011993:Recombinant Fusion Proteins; D013997:Time Factors
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D011241:Prednisone